New Delhi, Sep 18: The results of Fluid Accumulation Status Trial (FAST) clinical trial has established that fluid monitoring is a more accurate predictor of worsening heart failure compared to daily weight monitoring in heart failure patients with implantable devices.
In the clinical trial 156 heart patients implanted with ICD (implantable cardioverter-defibrillator) or CRT-D (cardiac resynchronization therapy-defibrillator) were monitored for an average of 18 months at 18 centers in the United States, Canada and Hong Kong.
And according to the test results released on Thursday, Sep 17, heart failure events detected in this study were within 30 days of a fluid index threshold crossing or an acute weight gain.
Speaking on the significance of the breakthrough, Padmshree Dr Balbir Singh, Senior Consultant, Electro-physiotherapy & Interventional Cardiology, Indraprastha Apollo Hospital said, "Treatment for other heart conditions, particularly myocardial infarctions (heart attacks), has improved substantially which means that more patients survive the short-term events and hence the number of people who are at risk for developing heart failure subsequently is on the rise. Another cause of worry for India is the increasing life expectancy. We all know that the risk of heart failure increases dramatically with age. Approximately, heart failure affects 10 out 1000 people above the age of 65."
Since OptiVol Fluid Status Monitoring, a feature available only in InSync Sentry which measures changes in fluid build up in the chest cavity, predicted 76 pc of future heart failure events as compared to only 23 pc detected by weight monitoring alone, fluid monitoring was three times more sensitive.
Apart from this, studies show that a combination of 'shock box' and pacemakers put together as a 'Combo' device would help reduce the risk of sudden cardiac arrest. In this method, the special CRT devices can potentially stop very fast heart rates by delivering an electrical shock to the patient.